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Protocol
AbstrACt
Introduction Retinopathy of prematurity (ROP) is 
a disease observed in extremely premature infants 
characterised by visioning-threatening retinal vessel 
proliferation. Propranolol, a drug used for decades in 
newborn infants with heart diseases, hypertension and 
thyrotoxicosis and licenced for infantile haemangiomas, 
may be effective in halting progression of ROP to severe 
stages, as suggested by preliminary data from small 
studies.
Methods and analysis ROPROP is an investigator-
initiated, multicentre, placebo-controlled double-blind, 
randomised controlled trial aiming to assess the safety 
and efficacy of orally administered propranolol to reduce 
the risk of threshold ROP (stage 3) in extremely preterm 
infants at 48 weeks postmenstrual age (primary objective) 
and the rate of infants requiring local interventions for 
severe ROP (secondary objective). Key inclusion criteria: 
gestational age <28 weeks, birth weight <1250 g, 
postmenstrual age ≥31 and <37 weeks, incipient ROP 
(stage 1 or 2, with or without plus disease) and written 
informed consent by parents or legal guardian. Key 
exclusion criteria: requirement for open-label propranolol 
treatment, major congenital malformations (including those 
with cerebrovascular malformations), known chromosomal 
anomalies, colobomas and other eye malformations, 
atrioventricular block grade 2 or 3 and comedication with 
antiarrhythmics, clonidine, insulin (pharmacodynamic 
interaction), phenobarbital or rifampicin (pharmacokinetic 
interaction). The intervention consists of oral propranolol-
hydrochloride (1.6 mg/kg/day in three to four divided 
dosages) or placebo until discharge, for a maximum of 10 
weeks. Analysis is by intention to treat.
Ethics and dissemination The protocol has received 
ethical and regulatory approval. Results will be published 
after peer review irrespective of the study outcome.
trial registration numbers NCT03083431 , EudraCT# 
2017‐002124‐24 (EUCTR), 00013730 (DRKS); Pre-results.
IntroduCtIon
Propranolol is a non-selective β blocker, first 
discovered in 19641 by James Whyte Black 
(Nobel Prize 1988). It is on the WHO’s List of 
Essential Medicines for Children2 and world-
wide available as a generic medication without 
age restrictions. Its long-standing indications 
include treatment of high blood pressure, a 
number of types of irregular heart rate, thyro-
toxicosis, migraine prophylaxis, performance 
anxiety and essential tremor. In infants and 
children, propranolol is used for prevention 
of paroxysmal supraventricular tachycardia, 
prevention of sudden ventricular fibrillation 
in long QT syndrome, prevention of blue 
spells in tetralogy of Fallot and treatment of 
hypertension in children with renal or cardio-
vascular disease. Moreover, propranolol has 
been found to lead to the regression of infan-
tile haemangiomas and has been licenced in 
2014 for this purpose in the European Union, 
Switzerland and the USA.
Retinopathy of prematurity (ROP) is a 
disorder of the developing retina observed 
only in low birthweight preterm infants that 
may lead to blindness in a small but signifi-
cant percentage of those infants. In preterm 
infants, retinal vessels are incompletely devel-
oped at birth and display a growth spurt 
peaking around 4–8 weeks before due term. 
Ophthalmoscopies performed during this 
growth spurt may reveal abnormal prolif-
eration of blood vessels that recede once 
vascularisation is complete. If the neovas-
cularisation, however, progresses to extra-
retinal fibrovascular proliferation into the 
vitreous (threshold ROP), there is a high 
risk of retinal detachment with subsequent 
blindness. Threshold ROP is associated with 
polymorphisms in a variety of genes, none of 
strengths and limitations of this study
 ► Repurposing of a well-known drug for a rare disease.
 ► Large, multicentre trial addressing a major public 
health concern.
 ► No commercial interests (investigator initiated and 
funded by public agencies).
 ► No central review of outcome possible.
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which cause retinopathy in the absence of prematurity. 
Vision-threatening ROP affects 10%–15% of extremely 
preterm infants with a gestational age below 28 weeks 
(0.7% of all newborns), with an overall incidence of 
about 5 cases per 1 000 000 inhabitants (orphan disease).
Currently available treatment of threshold ROP, 
consisting of laser ablation of the peripheral retina or 
intravitreal injection of antagonists of vascular endothe-
lial growth factor (VEGF), may prevent most but not all 
cases of permanent ROP-mediated blindness. Treated 
ROP is a strong independent predictor of later neuro-
developmental impairment in childhood and adoles-
cence.3–5 Both types of local treatment are associated with 
significant costs and side effects.6 Ablative laser surgery 
leads to permanent destruction of the peripheral retina 
(scars), while normal-appearing peripheral retinal vessels 
have been found to continue after intravitreal treatment. 
A large randomised controlled trial (RCT) has shown 
superior short-term and long-term results for intravit-
real injections of the anti-VEGF antibody, bevacizumab, 
as compared with laser treatment.7 8 Intravitreal bevaci-
zumab treatment, however, is completely off-label, as the 
antibody is not manufactured for intravitreal use and has 
never been licenced for infants. Other anti-VEGF antag-
onists made for intravitreal administration (ranibizumab, 
pegabtanib and aflibercept) are also not licenced in 
infants and have never been tested in an RCT. Despite 
these limitations, intravitreal anti-VEGF administration 
has become the preferred treatment for threshold ROP 
in several countries. ROP prevention and treatment 
figure high on the list of priority conditions requiring 
study in newborns.
The pathophysiological pattern of ROP is reminiscent 
to the natural history of infantile haemangiomas, which 
are also more common in preterm infants. There is 
conflicting evidence as to the antiangiogenic efficacy of 
propranolol in mouse models of oxygen-induced retinop-
athy that recapitulate several aspects of ROP.9–11 Prelimi-
nary results from two open-label comparison studies12 13 
and three RCTs14–16 suggest that oral propranolol admin-
istered at 1–2 mg/kg/day may be effective in halting 
progression of ROP to severe stages. In an open-label 
comparison study12 conducted in Chile, 2 of 20 preterm 
infants with ROP ≥ stage 2 on propranolol (1.5 mg/kg/
day in three divided doses) underwent laser treatment, 
as opposed to 13 of 27 historical control infants (p<0.01). 
In an open-label single-centre comparison study from 
Kayseri, Turkey,13 4 of 83 preterm infants on propran-
olol (2 mg/kg/day in four divided doses) underwent 
ablative laser surgery for ROP, as opposed to 8 of 88 
control infants (p>0.1). Two RCTs (NCT01238471 and 
NCT0107915) allocated a total of 72 preterm infants with 
stage 2 ROP to oral propranolol or control14 15 and found 
a similar reduction of infants requiring treatment (rela-
tive risks 0.44 and 0.42, respectively). The relative risk 
of the two trials combined is 0.44 (95% CI 0.19 to 1.02), 
translating in a number needed to treat of 5.17 A third 
RCT (CTRI/2013/11/004131) randomised 109 preterm 
infants with gestational age between 26 and 32 weeks to 
prophylactic propranolol (1 mg/kg/day divided in two 
doses) on the day 7 of life or placebo, until a corrected 
gestational age of 37 weeks or complete vascularisation 
of retina, whichever was later.16 Of 51 evaluable infants 
on propranolol, 13 infants underwent treatment for ROP 
(laser or intravitreal VEGF antagonist), as opposed to 
24/51 controls (p=0.0235).
An overview of published results of trials is given in 
table 1.
Further registered clinical trials evaluating the use of 
oral propranolol in preterm infants with early stages of 
Table 1 Overview of pilot trials assessing oral propranolol for treatment or prevention of retinopathy of prematurity (ROP)
Study
Participants 
propranolol
/controls
Gestational 
age (weeks)
Birth 
weight (g)
Dosage 
propranolol 
(mg/kg/day) Duration (day)
Rate ROP 
intervention 
propranolol 
versus controls Side effects
Makhoul et al14 10/10 24–28 854±240 2.0 (3×0.67) 16.3±6.7
(max 28)
2/10 versus 4/10 None
Filippi et al15 26/26 23–25
26–32
691±127
860±244
1.0 (4×0.25)
2.0 (4×0.5)
66±31 (6–90) 4/25 versus 
10/26
5/26
hypotension 
bradycardia 
bronchospasm
Sanghvi et al16 55/54 26–32 1235±280 1.0 (2×0.5) 32
(7–72)
13/51 versus 
24/51
None
Bancalari et al12 20/27 26.6±1.6 937±285 1.5 (3×0.5) 58±18 2/20 versus 
14/27
None
Korkmaz et al13 83/88 28.0±2.5 885±318 2.0 (4×0.5) No data 4/83 versus 8/88 None
(all) 194/205 23–32 1.0–2.0 25/189 versus 
60/202
5/194
hypotension 
bradycardia 
bronchospasm
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ROP (WHO International Clinical Trials Registry Plat-
form, http:// apps. who. int/ trialsearch/ default. aspx) 
have no results yet:
 ► IRCT2015102524681N1 is a parallel-assignment 
non-placebo-controlled trial from Guilen, Iran, for 
infants with early stages of ROP using oral propran-
olol at 2 mg/kg/day divided in four doses for infants 
with a gestational age of 26–31 weeks and 1 mg/kg/
day divided in four doses for infants with a gestational 
age of 23–25 weeks (target sample size, n=50). Recruit-
ment started in 2015 and is ongoing.
 ► NCT02977000 is a single-group assignment trial from 
Zhengzhou, China, which treats preterm newborns 
with a gestational age below 32 weeks and stage 2 ROP 
with oral propranolol (target sample size, n=100). 
Recruitment started in 2016 and is ongoing.
 ► NCT03038295 is placebo-controlled RCT from 
Guangdong, China, comparing oral propranolol 
(0.25 mg/kg/day) and propranolol eye drops (0.2%) 
versus placebo in preterm infants below 1500 g birth 
weight and early stages of ROP (target sample size, 
n=100). The study is not recruiting yet.
An Italian trial with topical therapy using 0.1% propran-
olol eye drops (EudraCT 2013-002062-39) planned 
according to the Simon optimal two-stage design for phase 
II clinical trials was discontinued early after recruiting 23 
patients before starting the second stage since the number 
of failures was above the set threshold.18 Subsequently, 
a multicentre open-label pilot study (NCT02504944, 
EudraCT 2014–0 05 472–29) investigating the use of 0.2% 
propranolol eye drops in infants with stage 1 ROP (target 
sample size, n=96) has been launched that is currently 
recruiting patients.19
Based on the effect size calculated from the trials that 
have results, all of these individual trials are considered 
underpowered to detect a significant difference in major 
ophthalmic outcomes. The ROPROP trial has been 
designed to investigate the safety and efficacy of oral 
propranolol administered to preterm infants with incip-
ient ROP aimed at reducing the rate of progression to 
severe ROP with an adequate sample size.
MEthods And AnAlysIs
Patients
Each patient must meet all of the following criteria to be 
enrolled in this double-blind RCT:
 ► Preterm infant born before 28 weeks’ gestation.
 ► Birth weight below 1250 g.
 ► Alive at 5 weeks of age.
 ► Postmenstrual age 31 0/7–36 
6/7 weeks.
 ► Ophthalmoscopic evidence of incipient ROP (stage 1 
or 2, with or without plus disease).
 ► Written informed consent by parents or legal 
guardian, including saving and propagation of pseu-
donymous medical data for study purposes.
Patients meeting any of the following criteria are not 
eligible for enrolment:
 ► ROP stage 3 at time of inclusion (endpoint already 
reached).
 ► Thyrotoxicosis, arterial hypertension or congen-
ital heart diseases requiring open-label propranolol 
treatment (such as tetralogy of Fallot, paroxysmal 
supraventricular tachycardia or long QT syndrome).
 ► Atrioventricular block grade 2 or 3 (contraindication 
for propranolol).
 ► Sinoatrial block (contraindication for propranolol).
 ► Uncontrolled heart failure or cardiogenic shock 
(contraindication for propranolol).
 ► Acute severe infection (inclusion may be postponed 
until infection has resolved).
 ► Bronchial asthma.
 ► Major congenital malformations or known chromo-
somal anomalies.
 ► Colobomas and other eye malformations.
 ► PHACE syndrome (posterior fossa anomalies; large 
infantile haemangiomas of the face, neck and/or 
scalp; arterial lesions; cardiac abnormalities/coarcta-
tion of the aorta; and eye anomalies) (risk of cerebro-
vascular complications).
 ► Very large haemangioma (risk of hyperkalaemia), as 
judged by the attending physician.
 ► Heart rate consistently (>1 hour) <100/min.
 ► Non-invasive mean arterial pressure consistently 
(>1 hour) <40 mm Hg.
 ► Medication of the infant or the mother if breast feeding 
with clonidine, reserpine, angiotensin converting 
enzyme (ACE) inhibitors, angiotensin-receptor 
antagonists (contraindicated in preterm infants) 
or antiarrhythmic drugs including amiodarone, 
propafenone, lidocaine, digoxin/digitoxin, quini-
dine, verapamil, diltiazem and bepridil (pharmacody-
namic interaction).
 ► Medication of the infant with rifampicin or phenobar-
bitone (enhanced metabolic clearance).
 ► Concurrent treatment with insulin (risk of 
hypoglycaemia).
 ► Severe liver dysfunction (GPT, alanine aminotrans-
ferase >900 U/L).
 ► Chronic kidney impairment (serum creati-
nine >1.3 mg/dL (100 µM))
 ► Persistent hypoglycaemia (blood glucose <36 mg/dL 
(2.0 mM) in three consecutive samples immediately 
preceding enrolment).
 ► Persistent hyperkalaemia (venous serum potas-
sium >5.9 mM in three consecutive samples immedi-
ately preceding enrolment).
 ► Persistent neutropenia (absolute neutrophil 
counts <1000/µL in three consecutive samples imme-
diately preceding enrolment).
 ► Known hypersensitivity to propranolol or any of the 
excipients.
 ► Prinzmetal’s angina, Raynaud’s phenomenon (severe 
peripheral arterial circulatory disturbance) or pheo-
chromocytoma (contraindications for propranolol in 
adults, not occurring in newborn infants).
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 ► Participating in another pharmacological interven-
tional clinical trial.
 ► Any circumstances that make the investigator believe 
that participation in the study leads to exceptional 
medical or organisational problems for the patient.
Enrolment, randomization and allocation concealment
Infants who meet all inclusion criteria and whose parents/
legal representatives have given their written informed 
consent will be reported to the trial centre and are the 
subjects of the central enrolment procedure. Each partic-
ipating unit will keep an enrolment log of preterm infants 
born before 28 weeks’ gestation with a birth weight below 
1250 g, containing date of birth, sex, gestational age, birth 
weight, death/date of death, transfer/dates of transfer, 
discharge/date of discharge, dates and results of ophthal-
moscopies (International Committee for the Classifica-
tion of  Retinopathy of Prematurity (ICROP) stage).
Every patient will receive an enrolment number, which 
will be unique for this individual patient. Patients who 
pass all inclusion and exclusion criteria, laboratory tests 
and ECG and are therefore eligible for the study will be 
randomised. In order to distribute possible confounding 
variables evenly in both groups, the patients will be 
randomised, with stratification of centre and gestational 
age. This randomisation will be done centrally using 
the randomisation tool within the study software secu-
Trial. The randomisation scheme incorporating variance 
minimisation will be used to assign infants, in a 1:1 ratio, 
to verum or placebo, with stratification according to 
gestational age (<26 weeks vs ≥26 weeks) and study site. 
Sequences of patient numbers will be assigned to each 
study centre and kept confidential, using sequentially 
numbered blinded medication boxes. The study medica-
tion (propranolol or placebo) will be randomly assigned 
to each patient number. Each bottle of the study medica-
tion has a unique medication number in the study medi-
cation list (unblinded) and will be manually linked to the 
assigned random patient number. The randomisation 
documentation (‘key list’) is subject to monitoring. Treat-
ment allocation will only be known to the pharmacist and 
the unblinded person. Neither the neonatologists taking 
care of the baby, nor the ophthalmologists performing 
the opthalmoscopies (the actual outcome assessors) will 
be aware of the assignment.
Intervention and comparator
The intervention consists of oral propranolol (1.6 mg 
propranolol hydrochloride/kg/day in 3–4 divided 
dosages) given for 4–10 weeks (depending on postmen-
strual gestational age at birth) or placebo. The study 
medication (1 mg/mL propranolol hydrochloride solu-
tion or placebo) will be provided and labelled by the 
good manufacturing practice (GMP) licenced Univer-
sity Pharmacy of Erlangen, Germany, as a solution in 
screw-capped bottles. The oral solution contains sucrose 
(25 g/100 mL), potassium sorbate (0.15 g/100 mL), citric 
acid monohydrate (0.07 g/100 mL), orange flavour and 
distilled water as excipients. The bottles are stored at 
room temperature. The solution is drawn into a syringe 
and administered by mouth or gastric gavage together 
with feeds. If the infant does not drink the medication, 
it will be given by gavage, but there is no replacement 
dose in case an infant vomits. If enteral feeding is stopped 
completely for any reason, the study medication will be 
temporarily discontinued and gradually resumed when 
enteral feeding is reinstituted.
The starting dose is 0.4 mg/kg/day (=0.4 mL/kg/d) 
by mouth or gavage in four divided dosages (ie, every 
6±1.5 hours) together with feeds, followed by incremental 
increases by 0.4 mg/kg every other day to a final dose of 
1.6 mg/kg/day (concentrations pertain to propranolol 
hydrochloride, to convert into propranolol base, multiply 
by 0.878). Once an infant is switched to feeding every 
4 hours, the total dose may be divided in three divided 
dosages (ie, every 8±2 hours). The duration of the study 
medication treatment is limited to 10 weeks. The study 
drug is reduced by 50% and discontinued the following 
day prior to discharge, when a decision has been made 
for local ROP treatment or when the infants is scheduled 
for surgery (eg, for inguinal hernia repair). No study 
medication will be given to patients out of hospital.
The study medication will be discontinued temporarily 
in the event of a lower respiratory infection associated 
with dyspnoea and wheezing or for any adverse clinical 
symptoms, as decided by the attending physicians. As 
soon as symptoms resolve, the maintenance dose is to be 
resumed but reduced by 50% and readjusted to the orig-
inal dose after 3 days. Attending physicians can hold or 
decrease doses of study drugs at their discretion in case 
of worsening disease or recurring adverse clinical symp-
toms. The study medication will be permanently discon-
tinued in the event of isolated bronchospasm or severe 
liver disease.
The following drugs may not be given concomitant 
with the study medication: antiarrhythmic drugs (all 
classes including amiodarone, propafenone, lidocaine, 
digoxin/digitoxin and calcium channel blockers), clon-
idine, reserpine, ACE inhibitors/angiotensin receptor 
antagonists (contraindicated in preterm infants), inhala-
tional anaesthetics (except during emergencies), rifam-
picin and phenobarbitone.
If an infant requires open-label propranolol during the 
study, the infant will be taken off the study drug, and the 
data will be censored for the efficacy analysis.
If a mother who breast feeds her infant starts taking 
propranolol, steroids, rifampicin or phenobarbitone, the 
investigator will be informed while breast feeding may 
continue. It will be recorded, but this does not imply 
discontinuation of the study and will not change the 
primary or secondary efficacy analysis which is by inten-
tion to treat.
If a mother who breast feeds her infants starts to take 
antiarrhythmic drugs (all classes including amiodarone, 
propafenone, lidocaine, digoxin/digitoxin and calcium 
channel blockers), clonidine, reserpine, ACE inhibitors 
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or angiotensin-receptor antagonists, the infant will be 
taken off the study drug, and the data will be censored 
for the efficacy analysis.
outcome and time frame
The primary endpoint for efficacy is survival until 48 
weeks postmenstrual age without ROP stage 3 (any zone), 
as diagnosed according to the International Committee 
for the Classification of Retinopathy of Prematurity Revis-
ited.20 ROP stage 3 is characterised by extraretinal prolif-
eration of blood vessels into the vitreous and a threshold 
for local therapy (laser or intravitreal injections of 
VEGF antagonists). Because there may be more than one 
ROP stage in the same infant (and actually the same eye), 
the ROP stage of the infant in this trial is determined by 
the most severe manifestation present. Retinopathy is 
diagnosed by an ophthalmologist blinded to the group 
assignment (experimental intervention or control). 
Death is included as a competing terminal event as it may 
occur before ROP has progressed to its peak stage.
The secondary endpoint for efficacy is survival until 
48 weeks postmenstrual age without local treatment for 
ROP (ablative laser surgery or intravitreal injections of 
anti-VEGF agents). Treated ROP is associated with neuro-
developmental impairment at 2, 5 and 11 years of age.3–5
Safety is gauged by the incidence of the following 
major events: death, necrotising enterocolitis (requiring 
surgery), culture-proven sepsis or meningitis (defined as 
growth of a recognised pathogen not counting coagu-
lase-negative staphylococci in blood or cerebrospinal fluid 
in an infant treated for at least 5 days with intravenous 
antibiotics and a rise of C reactive protein to more than 
10 mg/L during the first 72 hours of antibiotic treatment), 
symptomatic hypoglycaemia (blood glucose <30 mg/
dL requiring intravenous glucose administration for 
48 hours or more) and emergency endotracheal intuba-
tion (excluding elective intubation for surgery).
Exploratory continuous scale secondary outcomes are 
duration of supplemental oxygen and duration of hospi-
talisation (relative to the date of due term delivery), 
lowest heart rate and mean arterial pressure while the 
infant received study medication, average relative gain of 
weight and head circumference between start and end of 
the study medication.
sample size calculation
The ROPROP study is designed to demonstrate the 
superiority of oral propranolol in comparison with 
placebo in increasing the rate of infants surviving to 
48 weeks postmenstrual age without threshold ROP 
(primary endpoint). Assuming a rate of 30% of infants 
who will progress to threshold ROP or die,21 262 infants 
(131 in each group) will have to be analysed to have 
80% power (at a two-sided alpha level of 5%) to detect 
a 50% lower risk in the treatment group (two-sided 
Fisher’s exact test-based calculations, G*power 3.1.9.2, 
2014).22 With an anticipated loss to follow-up of 5% 
(withdrawal or other reasons), the total number of 
infants allocated to treatment will be 276. Assuming 
that 10% of eligible patients will not be recruited for 
lack of parental consent and 3% for medical or organ-
isational exclusion criteria, a total of 312 patients will 
be assessed for eligibility. This translates to 624 patients 
screened by funduscopy, assuming a rate of incipient 
ROP of 50%, and 718 infants below 28 weeks’ gesta-
tional age admitted to neonatal care, assuming an early 
mortality rate of 15%.
statistical analysis plan
The ROPROP study is designed to demonstrate the supe-
riority of oral propranolol in comparison to placebo in 
increasing the rate of infants surviving to 48 weeks post-
menstrual age without ROP stage 3 or more (primary 
endpoint).
Null hypothesis
There is no difference in the rate of infants surviving to 
48 weeks postmenstrual age without ROP stage 3 or more 
between infants treated with oral propranolol and infants 
treated with placebo.
Alternative hypothesis
There is a difference in the rate of infants surviving to 48 
weeks postmenstrual age without ROP stage 3 or more 
between infants treated with oral propranolol and infants 
treated with placebo.
The following populations will be described and 
analysed:
 ► The screened population will comprise all screened 
patients. The screened population will be described 
in terms of the reasons for exclusion from rando-
misation. No analysis will be done for the screened 
population.
 ► The intention-to-treat (ITT) population includes all 
randomised patients who received at least one dose of 
the study medication, with the exception of patients 
who are randomised in contradiction to one of the 
inclusion or exclusion criteria.
 ► The ‘Per Protocol population’ (PPP) will be based on 
the ITT. Patients treated with open-label oral propran-
olol will be excluded from the PPP.
 ► The safety population will include all infants who ever 
received the study drug.
The primary and secondary endpoints will be analysed 
in the ITT and PPP, while safety endpoints will be analysed 
in the safety population.
The primary endpoint for efficacy is survival until 48 
weeks postmenstrual age without ROP stage 3 or more 
(any zone), as diagnosed according to the ICROP Revis-
ited (12). The proportion of infants who have reached 
the primary endpoint will be compared and statistically 
assessed by means of a two-sided Fisher’s exact test to 
examine the null hypothesis of equal proportions in 
the groups of infants allocated to placebo and to oral 
propranolol, respectively. Effect sizes will be described by 
calculating the relative risk as well as the OR and 95% CIs.
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The confirmatory analysis of the primary efficacy 
endpoint will be by ITT, based on all patients who were 
randomised according to the inclusion and exclusion 
criteria and who received at least one dose of the study 
medication.
To consider the influence of site and gestational age 
(<26 weeks vs ≥26 weeks), these variables will be included 
in a logistic regression analysis. Survival until week 48 
without ROP stage 3 or more will be the dependent vari-
able while treatment group, site and gestational age will 
be the independent variables.
To handle patients with unknown status of the primary 
endpoint, a sensitivity analysis will be carried out in 
three steps: (1) patients with missing values excluded 
(confirmatory analysis); (2) patients with missing values 
included, primary endpoint ‘yes’ (sensitivity analysis); 
and (3) patients with missing values, primary endpoint 
‘no’ (sensitivity analysis) (best and worst case scenario).
The secondary endpoint for efficacy is survival until 
48 weeks postmenstrual age without local treatment for 
ROP (ablative laser therapy or intravitreal injections of 
anti-VEGF agents). It will be analysed analogously to the 
primary endpoint.
The parameters for assessing safety are rates of death 
prior to discharge, necrotising enterocolitis (requiring 
surgery), culture-proven sepsis or meningitis (defined 
as growth of a recognised pathogen not counting coag-
ulase-negative staphylococci in blood or cerebrospinal 
fluid in an infant treated at least 5 days with intravenous 
antibiotics and a rise of C reactive protein to more than 
10 mg/L during the first 72 hours of antibiotic treatment), 
symptomatic hypoglycaemia (blood glucose <30 mg/dL 
requiring intravenous glucose administration) and emer-
gency endotracheal intubation (excluding intubation for 
surgery).
Continuous scale safety outcomes are duration of 
supplemental oxygen and duration of hospitalisation 
(relative to the date of due term delivery), lowest heart 
rate and mean arterial pressure while the infant received 
study medication, average weekly gain of weight and 
head circumference between start and end of the study 
medication.
Summary tables will list discrete variables by absolute 
and relative frequencies, and continuous variables will be 
given by median, minimum, maximum and IQR for each 
treatment group. Discrete variables will be compared 
using Fisher’s exact tests, while continuous variables will 
be compared by the Wilcoxon test.
Adverse events (AE) and serious adverse events (SAE) 
will be analysed descriptively per group using absolute 
and relative frequencies.
The significance level in all tests will be set at 0.05, 
except for the interim analysis. All p values except for 
the confirmatory analysis and the interim analysis of the 
primary endpoint are considered to be exploratory (no 
adjustment for multiple testing).
One formal interim analysis for efficacy is planned, 
after half of the patients have been enrolled in the trial 
and have reached 48 weeks’ gestational age. The statistical 
observation will be done for a significance level of 0.001 
(two sided) (adjustment according to Peto-Haybittle). 
The interim analyses will be conducted by a statistician 
using coded group labels A and B blinded for the actual 
therapy groups.
To allow for patient-level meta-analyses, deidentified 
individual participant data that underlie the results 
reported will be supplied to investigators whose proposed 
use of the data has been approved by an independent 
review committee (learnt intermediary) during a limited 
period of time for individual participant data meta-anal-
ysis. For strict deidentification, only year of birth (instead 
of date of birth), country (but not site) and birth weight 
category (by 100 g intervals) will be allowed.
Patient and public involvement
Patients or public were not involved in the design or 
conduct of the study, and no attempt was made to assess 
the burden of the intervention by patients themselves.
EthICs And dIssEMInAtIon
 Ethical and regulatory approval will be obtained for each 
participating site prior to commencement of recruit-
ment in all countries (Germany, Israel, Switzerland and 
Turkey). The trial has not started recruitment at the time 
the protocol is being submitted for publication. The 
results of the trial will be published irrespective of the 
outcome of the study.
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